Functional tests associated with sarcopenia in moderate chronic obstructive pulmonary disease

Area of Science:

• Pulmonary Medicine
• Geriatrics
• Sports Medicine

Background:

• Sarcopenia, characterized by age-related loss of skeletal muscle mass and function, is a common comorbidity in chronic obstructive pulmonary disease (COPD).
• Identifying sarcopenia in COPD patients is crucial for managing disease progression and improving patient outcomes.
• Current screening methods may not be practical or accessible for all COPD patients.

Purpose of the Study:

• To investigate the association between various physical and functional performance measures and sarcopenia in individuals with moderate COPD.
• To determine reliable cutoff points for sarcopenia screening using accessible functional tests in this population.

Main Methods:

• A cohort of individuals with moderate COPD, aged over 50, with and without sarcopenia, were recruited.
• Assessments included lung function, body composition, grip strength, Short Physical Performance Battery (SPPB), 5, 10, and 30-second sit-to-stand tests (5STS, 10STS, 30STS), 6-minute walk test, respiratory muscle strength, and physical activity levels.
• Receiver operating characteristic (ROC) curve analysis was used to establish cutoff points and evaluate discriminatory power.

Main Results:

• Participants with COPD and sarcopenia exhibited significantly lower lean mass, body fat, body mass, and performance in 10STS, 30STS, SPPB, and gait speed compared to the non-sarcopenic group.
• Optimal cutoff points for sarcopenia screening were identified as 10.88 s (10STS), 34.14 s (30STS), 15 repetitions (5STS), and 10 points (SPPB).
• The 30STS and SPPB demonstrated acceptable discriminatory power for identifying sarcopenia, with no significant differences found between the functional tests' ROC curves.

Conclusions:

• Functional tests, specifically the 30-second sit-to-stand (30STS) and Short Physical Performance Battery (SPPB), are simple, cost-effective tools for screening sarcopenia in moderate COPD patients.
• These validated cutoff points can aid clinicians in early identification and management of sarcopenia in this vulnerable population.